Two anti-PD-1 antibodies approved by the FDA, pembrolizumab and nivolumab, have shown efficacy in many cancer types, nevertheless there are some indications where limited efficacy is observed. Tislelizumab (BGB-A317), an investigational anti-PD-1 antibody, has demonstrated significant clinical ...
Gavreto, a RET-targeting NSCLC drug, was approved and marketed in China nine months after its FDA approval. The RWE study in Hainan played no small part in that, as it provided the single-arm trial Gavreto was conducting in China with supporting evidence. As the poster children for ...
BeiGene currently has three approved medicines discovered and developed in our own labs: BTK inhibitor BRUKINSA in the United States, China, the EU and U.K., Canada, Australia and additional international markets; and the non-FC-gamma receptor binding anti-PD-1 antibody...
Wisconsin Carbone Cancer Center in Madison is studying an intratumoral (IT) vaccine strategy with the GD2-reactive hu14.18-IL2 immunocytokine (IC) in patients with advanced (stage IV) or unresectable stage III melanoma who have disease progression after prior treatment with an FDA-approved therapy....
Ivonescimab plus chemotherapy improved survival in advanced squamous NSCLC vs tislelizumab and chemotherapy in a phase 3 trial. Read More Expert Panel Addresses 5 Areas of Need in Metastatic Prostate Cancer Morgan Bayer April 23rd 2025 Article ...
The FDA hasn't waded into the debate over Flamin' Hot Cheetos, but the popular snack food has become public enemy #1 in school districts around the country. Since the early 2010s, schools in states like California, New Mexico, and Illinois have banned the snack due to their lack of nutri...